Neok Bio has exited stealth with $75 million to take a pair of bispecific antibody-drug conjugates sourced from ABL Bio into the clinic. ABL, a Korean biotech that is partnered with companies ...
- Backed by ABL Bio, a world leader in antibody engineering, NEOK is advancing a pipeline of differentiated bispecific antibody drug conjugates for a wide range of solid tumors - Company plans to ...
This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Neok Bio emerged from stealth on Tuesday with $75 ...
This IND clearance marks an important milestone for NEOK002, an EGFR/MUC1-targeting ADC candidate developed by NEOK Bio and built on a bispecific antibody originally developed by Biocytogen and ...
Company plans to initiate a Phase 1 clinical study by 1H2026 and share data in 2027 NEOK Bio, Inc., an oncology therapeutics company focused on the development of novel antibody drug conjugates (ADCs) ...
Neok Bio Inc. was formed earlier this year and is already on schedule to file an IND in a few months for its two bispecific antibody-drug conjugates (ADCs) to treat various types of tumors. The ...
Second candidate in NEOK’s differentiated ADC pipeline to enter the clinic in 2026 Company plans to initiate a Phase 1 clinical study for NEOK002 in 2Q2026 and share data in 2027 NEOK Bio, Inc., an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results